H.R. 6963 · 117th Congress · House

Accelerated Approval Integrity Act of 2022

Active· Referred to the Subcommittee on Health.
Introduced
Mar 7, 22
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Accelerated Approval Integrity Act of 2022

This bill establishes requirements relating to postapproval studies for drugs that receive accelerated approval for serious or life-threatening diseases or conditions, such as requiring product sponsors to agree in advance to conduct such studies and terminating product approval if certain benchmarks are not met.

Action Timeline

4
  1. MAR 08, 2022Committee

    Referred to the Subcommittee on Health.

  2. MAR 07, 2022IntroReferral

    Introduced in House

  3. MAR 07, 2022IntroReferral

    Introduced in House

  4. MAR 07, 2022IntroReferral

    Referred to the House Committee on Energy and Commerce.

Committees

2

Health Subcommittee

hsif14

Referred: Mar 8, 2022

Active

Energy and Commerce Committee

hsif00

Referred: Mar 7, 2022

Active